Skip to content

FANMI: Community Cohort Care for HIV-Infected Adolescent Girls in Haiti

FANMI: Community Cohort Care for HIV-Infected Adolescent Girls in Haiti

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03286504
Enrollment
120
Registered
2017-09-18
Start date
2018-05-25
Completion date
2023-10-01
Last updated
2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Brief summary

The investigators will conduct a randomized controlled trial of Group Care in the GHESKIO Community Center versus Individual Care in the GHESKIO Adolescent Clinic for 160 HIV-infected adolescent girls age 16-23 years in Haiti (80 adolescents per arm). Group Care includes receiving integrated clinical and social support services in groups of 5-8 adolescents at a monthly visit. The primary outcome is retention in HIV care at 12 months after randomization.

Detailed description

The investigators will conduct a randomized controlled trial of Group Care in the GHESKIO Community Center versus Individual Care in the GHESKIO Adolescent Clinic for 160 HIV-infected adolescent girls age 16-23 years in Haiti (80 per arm). Adolescents randomized to Group Care will receive HIV services including integrated clinical and social support care in groups of 5-10. Adolescents randomized to Individual Care will continue to receive individual care at the GHESKIO Adolescent Clinic, which is the current standard of care (described below). If a subject declines to participate in the study they will continue to receive standard HIV care. Participants will be randomized to either Group Care or Individual Care in a 1:1 ratio using a computer generated random assignment. Individual Care (standard of care): Adolescents randomized to Individual Care will receive care in the GHESKIO Adolescent Clinic which cares for both males and females age 13-23 years. The Adolescent Clinic waiting room has a television showing educational videos. After seeing a triage peer counselor and having their vital signs taken, participants see a nurse practitioner (NP) one-on-one in a private room for a 10-15 minute clinic visit. The NP may also provide family support counseling including family visits per clinical judgment. Each NP sees approximately 20 HIV-infected adolescents per day. The adolescent then returns to the HIV positive peer counselor, who provides one-on-one counseling for 30 minutes on topics chosen by the adolescent and the counselor. Each counselor sees \ 10 adolescents per day. Group Care (intervention): Adolescent girls randomized to Group Care will join a group within one week of study enrollment and receive care in the GHESKIO Community Center. The investigators estimate that it will take 4-6 weeks to constitute a full group of 5-10. During this enrollment phase, groups will meet weekly, adding new participants each week. The participants will then meet monthly with an NP and a HIV positive peer counselor. Each monthly group session will last \ 2 hours. This is comparable to the time it takes for a patient to pass through the Adolescent HIV Clinic. It will start with a 30 minute unstructured discussion. This time is intentionally unstructured and responds to our previous research finding that adolescents want to talk about topics of their choosing with their peers. This will be followed by a 45 minute group counseling session following a structured curriculum, addressing topics such as social isolation, stigma, family support, sexual risk behavior, life goals, medication adherence, job skills, and transitions. This is followed by a 30 minute social activity led by two rotating group leaders who are elected by their peers. Social activities include crafts, playing cards, and charades. Participants will be seen one by one by the NP for \ 10-15 minutes in a screened in clinical area during the unstructured discussion and the social activity. All HIV clinical services, including provision of antiretroviral therapy (ART) medications, CD4 T cell monitoring, screening for symptoms and OI, medication adherence monitoring, family planning, and general primary care will be provided by the NP. Girls who become eligible for ART will be provided with individual counseling and promptly initiated on ART by the NP. The primary hypothesis is that Group Care will improve retention at 12 months compared with standard Individual Care. The study has \> 90% power to detect a difference in retention from 60% to 85%. Participants in both study arms will complete a questionnaire with a research nurse at enrollment, 6, and 12 months collecting data on HIV knowledge, HIV-related stigma, HIV disclosure, social and family support, depression and alcohol use, problem solving skills, and food insecurity.

Interventions

BEHAVIORALFANMI - Cohort Care

FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.

Sponsors

Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
CollaboratorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 23 Years
Healthy volunteers
Yes

Inclusion criteria

* Female * Age 16-23 years * ART naive, initiated ART in the past 3 months, or defaulted from care for 3 months or more * Participant knowledge of HIV-infection * Willing to receive care at the clinic or in the community * Willing to provide consent (age 18 -23 years) or assent with parental/guardian consent (16-17 years)

Exclusion criteria

* Pregnancy at the time of enrollment * A severe HIV/AIDS illness requiring hospitalization or intensive medical follow-up * Based on the primary clinician's judgement that the adolescent is at a developmental stage not suited for study participation

Design outcomes

Primary

MeasureTime frameDescription
12 Month Retention12 monthsRetention in care at 12 months will be measured. 12 month retention is defined as being alive at 12 months and having a care visit between 9 and 15 months after enrollment.

Secondary

MeasureTime frameDescription
Time to Antiretroviral Therapy (ART) Initiation12 monthsTime to ART initiation is the number of calendar days from date of HIV diagnosis to date of ART initiation.
Optimal Antiretroviral Therapy (ART) Adherence12 monthsART adherence will be measured by self-report using two questions: 1) number of pills missed in the past 4 days and 2) forgot to take pills last weekend. A response of no missed pills in the past 4 days and did not forget to take pills last weekend is defined as 'optimal' adherence. All other responses are defined as 'sub-optimal' adherence.
Sexual Risk Behavior12 monthsSexual risk behavior will be measured by regular condom use among those who are sexually active. Regular condom use is defined as a response of 'often' or 'always' when asked about condom use during sexual intercourse.
12 Month Viral Suppression12 monthsViral suppression at 12 months will be measured. Suppressed viral load will be defined as a binary outcome based upon the WHO definition of viral suppression as a plasma HIV-1 RNA level \<1000 copies/µl.
Acceptability12 monthsFANMI Acceptability will be assessed using qualitative interviews conducted at 6 and 12 months after study enrollment with a subset of 30 FANMI participants and clinic providers (nurses and peer educators). A trained qualitative research assistant will interview adolescents to explore attitudes about the FANMI intervention, specifically as it relates to social isolation, stigma, and family rejection, self-esteem and clinic-level factors.
Healthcare Utilization12 monthsHealthcare utilization will be measured. Healthcare utilization will be measured as a composite of attendance at HIV care visits, laboratory services, and use of other specialist services at study sites and use of health services at non-study sites such as hospitalizations or visits to other medical specialists.
Number of Sexually Transmitted Infections12 monthsSexually Transmitted Infections will include syphilis, diagnosed using a serum RPR (HUMAN) followed by a treponemal test if positive (Bioline Standard Diagnostics), chlamydia and gonorrhea, diagnosed by the urine GeneXpert GT/NG assay.

Countries

Haiti

Participant flow

Participants by arm

ArmCount
Standard-of-care
Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
60
FANMI - Cohort Care
Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-10 peers. The entire visit will take \ 2 hours. FANMI - Cohort Care: FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
60
Total120

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up1916

Baseline characteristics

CharacteristicStandard-of-careFANMI - Cohort CareTotal
Age, Categorical
<=18 years
6 Participants10 Participants16 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
54 Participants50 Participants104 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
60 Participants60 Participants120 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
60 Participants60 Participants120 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Sex: Female, Male
Female
60 Participants60 Participants120 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 601 / 60
other
Total, other adverse events
0 / 600 / 60
serious
Total, serious adverse events
0 / 600 / 60

Outcome results

Primary

12 Month Retention

Retention in care at 12 months will be measured. 12 month retention is defined as being alive at 12 months and having a care visit between 9 and 15 months after enrollment.

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Standard-of-care12 Month Retention41 Participants
FANMI - Cohort Care12 Month Retention44 Participants
p-value: 0.5595% CI: [-0.112, 0.212]Chi-squared
Secondary

12 Month Viral Suppression

Viral suppression at 12 months will be measured. Suppressed viral load will be defined as a binary outcome based upon the WHO definition of viral suppression as a plasma HIV-1 RNA level \<1000 copies/µl.

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Standard-of-care12 Month Viral Suppression26 Participants
FANMI - Cohort Care12 Month Viral Suppression28 Participants
p-value: 0.7195% CI: [-0.145, 0.211]Chi-squared
Secondary

Acceptability

FANMI Acceptability will be assessed using qualitative interviews conducted at 6 and 12 months after study enrollment with a subset of 30 FANMI participants and clinic providers (nurses and peer educators). A trained qualitative research assistant will interview adolescents to explore attitudes about the FANMI intervention, specifically as it relates to social isolation, stigma, and family rejection, self-esteem and clinic-level factors.

Time frame: 12 months

Population: Data for this outcome was not collected.

Secondary

Healthcare Utilization

Healthcare utilization will be measured. Healthcare utilization will be measured as a composite of attendance at HIV care visits, laboratory services, and use of other specialist services at study sites and use of health services at non-study sites such as hospitalizations or visits to other medical specialists.

Time frame: 12 months

Population: Data not collected.

Secondary

Number of Sexually Transmitted Infections

Sexually Transmitted Infections will include syphilis, diagnosed using a serum RPR (HUMAN) followed by a treponemal test if positive (Bioline Standard Diagnostics), chlamydia and gonorrhea, diagnosed by the urine GeneXpert GT/NG assay.

Time frame: 12 months

Population: There were 14 participants in the SOC arm and 13 subjects in the FANMI arm that did not receive STI testing and were excluded from this analysis.

ArmMeasureValue (NUMBER)
Standard-of-careNumber of Sexually Transmitted Infections10 incident STI diagnoses
FANMI - Cohort CareNumber of Sexually Transmitted Infections20 incident STI diagnoses
p-value: 0.0395% CI: [0.023, 0.393]Chi-squared
Secondary

Optimal Antiretroviral Therapy (ART) Adherence

ART adherence will be measured by self-report using two questions: 1) number of pills missed in the past 4 days and 2) forgot to take pills last weekend. A response of no missed pills in the past 4 days and did not forget to take pills last weekend is defined as 'optimal' adherence. All other responses are defined as 'sub-optimal' adherence.

Time frame: 12 months

Population: There were 18 participants in the SOC arm and 22 participants in the FANMI arm who chose not to respond to the ART adherence assessment and were not included in this analysis.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Standard-of-careOptimal Antiretroviral Therapy (ART) Adherence22 Participants
FANMI - Cohort CareOptimal Antiretroviral Therapy (ART) Adherence18 Participants
p-value: 0.6595% CI: [-0.269, 0.169]Chi-squared
Secondary

Sexual Risk Behavior

Sexual risk behavior will be measured by regular condom use among those who are sexually active. Regular condom use is defined as a response of 'often' or 'always' when asked about condom use during sexual intercourse.

Time frame: 12 months

Population: There were 21 participants in the SOC arm and 26 subjects in the FANMI arm that did not receive STI testing and were excluded from this analysis.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Standard-of-careSexual Risk Behavior21 Participants
FANMI - Cohort CareSexual Risk Behavior26 Participants
p-value: 0.0495% CI: [0.015, 0.438]Chi-squared
Secondary

Time to Antiretroviral Therapy (ART) Initiation

Time to ART initiation is the number of calendar days from date of HIV diagnosis to date of ART initiation.

Time frame: 12 months

Population: Participants analyzed were only those who were ART-naïve at study enrollment.

ArmMeasureValue (MEDIAN)
Standard-of-careTime to Antiretroviral Therapy (ART) Initiation0 days
FANMI - Cohort CareTime to Antiretroviral Therapy (ART) Initiation0 days

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026